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(SLE) (8%). Twenty-seven patients received allogeneic HCT (al-
loHCT) for SSC (n7), amyotrophic lateral sclerosis (n6), au-
toimmune cytopenias (n6), SLE (n2), autoimmune enteropathy
(n1) and unclassiﬁed AI (n3). The median age at HCT did not
differ by transplant type (41 vs. 36 years for autoHCT and allo-
HCT, respectively) and most patients (66%) had a good perfor-
mance score at HCT. The median time from diagnosis to trans-
plant was 58 and 34 months for autoHCT and alloHCT,
respectively. Irradiation-containing conditioning regimens were
used in 109 cases (61%) and cyclophosphamide either alone or in
combination with other agents without irradiation in 45 cases
(25%). Most autoHCT recipients received total body irradiation,
cyclophosphamide and anti-thymocyte globulin (64%). Peripheral
stem cell cells were the predominant graft type; and 56% of these
grafts were manipulated ex vivo (CD34 cell selection or T-cell
depletion). The probabilities of 100-day mortality were 10% (95%
conﬁdence interval [CI], 6-15%) and 17% (95% CI, 5-35%) after
autoHCT and alloHCT, respectively. Corresponding one-year
probabilities of overall survival were 89% (95% CI, 83-93%) and
75% (95% CI, 54-91%). One-year probability of overall survival
post-autoHCT were 96%, 82% and 73% for MS, SSC and SLE
respectively. In summary, these collective data from CIBMTR, MS
and SSC are the most common autoimmune disease indications for
HCT.
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AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AH-
SCT) FOR EARLY ONSET TYPE I DIABETES MELLITUS
Moraes, D.A.1, Oliveira, M.C.1, Stracieri, A.B.1, Couri, C.E.1,
Barros, G.M.1, Pieroni, F.1, Coutinho, M.A.1, Foss, M.C.1,
Simoes, B.P.1, Voltarelli, J.C.1 1Hospital das Clinicas/University of Sao
Paulo, Ribeirao Preto, Sa˜o Paulo, Brazil.
Introduction: Type I Diabetes mellitus (DM1) is an autoim-
mune disease that destroys pancreatic islet cells were insulin is
producted, leading to insulin dependence and chronic complica-
tions such as retinopathy, nephropathy, neuropathy and coronary
atherosclerosis.
Objectives: Evaluate the efﬁcacy and toxicity (phases I/II) of
high-dose cyclophosphamide (Cy) and rabbit anti-thymic globulin
(rATG) followed by rescue with AHSCT in patients with less than
6 weeks from diagnosis of type 1 Diabetes mellitus.
Materials and Methods: Stem cells were mobilized from the
bone marrow with Cy (2g/m2) and Filgrastim (10g/kg/d SC),
collected by leukapheresis and cryopreserved. Patients were con-
ditioned with Cy (50mg/kg x 4) and rATG (4.5 mg/kg), followed
by stem cell infusion.
Results: Since December 2003, 15 patients were enrolled in this
study. The medium age was 19.2 years, (14- 31 years), and the time
between diagnosis and mobilization was 34.7 days (24 to 49 days).
The mean hospitalization period was 24,2 days (16- 57 days) and
the average number of CD34 infused cells was 10.8106/kg
(5.8- 23.19106/kg). Neutrophil engrafted on days 8 to 10 (aver-
age of 9,3 days) and platelets engrafted on days 0 to 15 days
(average 12.3 days). There were no deaths. Most patients had
neutropenic fever, but only one developed serious complications
needing intensive care due to bilateral pneumonia, reversed with
antibiotic therapy and non-invasive ventilation. All patients were
using exogenous insulin therapy before mobilization, with an av-
erage dose of 0.38 Ul/kg (0.13 to 0.58 Ul/kg). In a mean follow-up
of 14.2 months (1- 31 months), insulin therapy was suspended in 12
patients from D-7 to D39 (average 32), two patients decreased
insulin dose (16 and 21% compared to the period before AHSCT)
and one patient remains using high dose insulin (1.7 Ul/kg/d). This
last patient was the only one that presented ketoacidosis pre-
AHSCT and received corticosteroids in the pre-conditioning pe-
riod. Six to twelve months after AHSCT, the peptide-C levels
considerably increased in 7 patients with clinical response and
glycated hemoglobin values are 7%.
Conclusion: These results indicate that high-dose immunosup-
pression associated with AHSCT may induce prolonged clinical
remission of Type 1 diabetes mellitus, without signiﬁcant toxicity.
The durability of response will be evaluated in longer follow-up.
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SERIAL SKIN BIOPSIES DEMONSTRATE REDUCED DERMAL FIBROSIS
AFTER AUTOLOGOUS HEMOPOIETIC STEM CELL TRANSPLANT (A-
HSCT) FOR SEVERE SYSTEMIC SCLEROSIS (SSS)
Shulman, H.M.1, Nash, R.A.1 1Fred Hutchinson Cancer Research Cen-
ter, Seattle, WA.
Background: In a multiinstitutional study, 34 patients with SSS
received high-dose immunosuppressive therapy followed by A-
HSCT. Serial evaluations included improvement in the modiﬁed
Rodnan skin score (mRSS, 51-0) and histologic dermal ﬁbrosis
score (DFS), grades 0-5.
Methods: 10 patients had 23 pre and post HSCT serial biopsies,
mean follow-up 4 years. Punch biopsies from each patient were
obtained from the same location on the lateral upper or lower arm.
The DFS was based on the depth and % of dermal homogeniza-
tion, size orientation and eosinophilia of ﬁbers, and interstitial
space between the fascicles in H&E -stained sections. The mRSS
showed a signiﬁcant improvement in 8/10 patients. The mean
decrease in mRSS of 34 patients’ (baseline 30.2) to ﬁnal evaluation
was 22.08 (-70.3%, and with a signiﬁcant linear decrease over time,
both p   0.0001). The DFS in 7 of 10 had 3 grades of
reduction. 3 had a ﬁnal DFS of 0 with reduction of dermal thick-
ness, loss of homogenization thinning and straightening of the
collagen bundles with an increase in interstitial space. The dermal-
epidermal border remained straightened with loss of rete ridges
and loss of elastica in the papillary dermis. The discordant ﬁnal
scores in patient 8, decrease in DFS without decrease in mRSS was
likely related to localized improvement of skin at site of biopsy.
Conclusion:
A-HSCT for SSS leads to remodeling of dermal collagen with
loss of sclerosis and corresponding improvements in the mRSS.
RESULTS: Assessment of dermal ﬁbrosis after A-HSCT for SSS
Patient
Baseline Final Score
mRSS/DFS Year/mRss/DFS
1 35/3 2/3/1
2 16/3 6/0/0
3 40/5 5/10/0
4 26/4 1/18/3
5 19/4 5/1/1
6 20/5 4/7/3
7 30/4 4/8/0
8 48/5 4/42/1*
9 44/5 4/10/1
10 29/5 3/12/2
AUTOLOGOUS TRANSPLANTS
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PREVENTION OF MUCOSITIS IN AUTO BMT/STEM CELL TRANSPLANT
PATIENTS
Klocke, J.1, Cannon, M.1, Gissenger, D.1, Devoe, C.1, John, V.1,
Bayer, R.-L.1 1North Shore University Hospital, 300 Community
Drive, Manhasset, NY.
It is estimated that 80% of patients who undergo high-dose
chemotherapy plus or minus radiotherapy prior to transplantation
develop mucositis. Mucositis is a painful complication, which can
lead to poor nutrition, increased use of narcotics, dehydration,
greater risk for infection and bacteremia, as well as altered quality
of life. Patients can have oral ulceration, epigastric discomfort,
diarrhea, rectal irritation, and bleeding. It is likely that the com-
plications of mucositis can contribute to increased lenght of stay
during stem cell transplantation.
The purpose of this study is to compare patients who received
Kepivance(palifermin) as part of their treatment with patients that
did not receive this medication during autologous stem cell trans-
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plantation. We performed a retrospective analysis of 70 patients;
20 prior to the institution of Kepivance(palifermin), and 50 pa-
tients after. The preparative regimens include Melphalan, Busulfan
& Etoposide, Cytoxan, BCNU, Etoposide, and Busulfan & Cy-
toxan.
The average length of stay for non-Kepivance patients was 32.3
days compared to 28 days in patients who received the drug. The
severity of both oral and GI mucositis appeared to be less. 85% of
non-Kepivance patients experienced diarrhea or rectal irritation,
versus 52% with Kepivance. Neutropenic fever was noted in 95%
of patients that did not receive the drug and 76% of the patients
that did. There was a trend torward earlier engraftment in the
Kepivance group.
Kepivance seems to have had a positive effect on our patients.
This updated study suggests an improvement in mucositis symp-
toms with the use of Kepivance(palifermin). It appears that mu-
cositis and its treatment contribute to the length of stay and costs
of stem cell transplantation. Qualtiy of life for these patients can be
greatly improved if mucositis is reduced during the course of stem
cell transplantation.
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ROLE OF HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM
CELL TRANSPLANTATION IN PRIMARY SYSTEMIC AMYLOIDOSIS: A
SYSTEMATIC REVIEW
Behera, M.1, Kharfan-Dabaja, M.A.1, Kumar, A.1, Soares, H.P.1,
Djulbegovic, B.1 1H. Lee Mofﬁtt Cancer Center and Research Institute at
the University of South Florida, Tampa, FL.
Background: Primary systemic amyloidosis (AL) is a rare plasma
cell clonal disorder(8/million) characterized by extracellular depos-
its of material composed mainly of fragments of light chain immu-
noglobulin throughout a body. Standard chemotherapy (e.g. mel-
phalan and prednisone) is associated with poor outcomes (typical
median survival is between 12-18 months with less than 5% sur-
viving 10 years). Autologous stem cell transplant (ASCT) has been
increasingly advocated for the treatment of AL. However, it is
uncertain whether ASCT is better than standard chemotherapy.
To address this uncertainty, we undertook a systematic review/
meta-analysis to evaluate the efﬁcacy of high-dose chemotherapy
and autologous stem-cell transplant (HSCT) versus conventional
chemotherapy in patients with AL.
Methods: We searched for all published studies in Medline and
Cochrane library databases. In addition, we hand searched for
references. Studies were included if they were comparison trials of
HSCT versus conventional chemotherapy, regardless of the trial
design (e.g. randomized controlled trials [RCTs] or prospective
studies with historical control). The studies were eligible if patients
had biopsy proven AL with at least one major organ involved .Data
were extracted on beneﬁts as well as harms (overall survival, event-
free survival, response, treatment related mortality, treatment-
related morbidity).
Results: Out of 34 identiﬁed studies only 4 met the inclusion
criteria for the current systematic review, two of which were RCTs
and two were prospective non-randomized trials that included histor-
ical control. The ages of patients were in the range of 18-69 years.
When we pooled all the data, we found that overall survival was
similar for ASCT and conventional therapy arms [hazard ratio (HR)
of 1.10 (95% CI 0.88, 1.36, p0.4); no signiﬁcant heterogeneity was
found; p 0.6]. Analysis of data according to design (randomized vs.
non-randomized trials) resulted in similar results [HR1.10 (95% CI
0.88, 1.37) and HR0.98 (95% CI 0.29, 3.35), respectively]. The
complete hematologic response was also similar between the 2 arms
[OR 1.38 (95% CI 0.67, 2.85; p0.4].
Conclusion: The results from the meta-analysis indicate that
there is no statistically signiﬁcant difference between the treatment
effects from high-dose chemotherapy with ASCT and conven-
tional chemotherapy. Hence, the efﬁcacy of ASCT in improving
overall survival and complete hematologic response remains to be
proven.
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DOSE DENSE DREIFACH* MELPHALAN100 FOR MULTIPLE MYELOMA
Berz, D.1, McCormack, E.2, Winer, E.2, Karwan, P.2, Colvin, G.2,
Rathore, R.2, Larry, L.2, Elfenbein, G.2, Quesenberry, P.2 1Brown
University, Providence, RI; 2Roger Williams Medical Center, Provi-
dence, RI.
Background: Tandem high dose melphalan therapy with autolo-
gous peripheral stem cell support has emerged as standard of care for
patients without prohibitive comorbidities. Mucositis and gastrointes-
tinal side effects are the most common extrahematologic side effects.
Two previously published studies presented a triple transplant with a
conditioning regimen melphalan 100mg/m2 (MEL100) with periph-
eral stem cell support every two to ﬁve months schedule for patients
with prohibitive comorbidities for high dose tandem transplantation.
We are presenting a novel approach that investigates the triple mel-
phalan100/m2 approach on a dose dense, every three weeks schedule
in a patient population without signiﬁcant comorbidities.
Patients andmethods:Thirteen standard or high risk patients with
stageIII multiple myeloma were prospectively treated. This popula-
tion contained eight patients with IgG clonality, 3 IgA, 1 nonsecretory
and one light chain isotype. The induction regimens of the thirteen
patients were heterogenous and included 5 VAD, 3 DCIE, 2 Thal/
Dex, 2 CIE and 1 pulse decadron. Patients underwent peripheral
blood leukopheresis, and these cells were divided into three equal sets
and frozen. The patients were scheduled to receive Melphalan at
100mg/m2 on day -1, 20, and 41 and then the autologous infusions
occurred at day 0, 21, and 42.
Results: All patients were able to receive all three cycles of the
MEL100 regimen. Seven patients (54%) received the treatments on
the every three week schedule; three treatments (23%) during the
second cycle and six treatments (46%) of the third cycle had to be
delayed a median of 6 and 4 days respectively. Three patients were
managed completely in the outpatient setting, and the average total
hospital stay for the three transplants was 18 days.Median progression
free survival was 854 days (range 73 – 1571) and the overall survival of
this cohort has yet to be reached. No patient had worse than grade II
mucositis, and no serious adverse events were recorded.
Conclusions:Our regimen of three consecutive autologous periph-
eral stem cell transplants with a reduced dose of melphalan at
100mg/m2 given every three weeks is very well tolerated. The pro-
gression free survival and overall survival are similar and can be
compared favorably with the standard tandem myeloma regimens.
Our data is intriguing and further studies with larger numbers need to
be performed to conﬁrm these results. *German for triple.
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OUTCOMES ASSOCIATED WITH AGE IN PATIENTS WITH MALIGNANT
LYMPHOMA RECEIVING AUTOLOGOUS STEM CELL TRANSPLANT
Beveridge, C.A.1, Ershler, W.B.2, Orloff, G.J.1, Sheridan, M.J.3,
Shelton, M.V.1 1Fairfax Northern Virginia Hematology-Oncology, PC,
Fairfax, VA; 2Institute for Advanced Studies in Aging, Washington,
DC; 3Inova Fairfax Hospital, Falls Church, VA.
Background and Rationale
Older age is frequently considered a contraindication to high
dose therapy. We evaluated 32 auto-transplant patients with Ma-
lignant Lymphoma (ML) to determine whether outcomes for those
60 years of age differed from those 60 years of age.
Material and Methods
A retrospective assessment was undertaken of ML patients who
were transplanted at Inova Fairfax Hospital from 2004-2006. All
patients had Karnofsky performance scores of 80% and all were
apheresed using a high volume technique and ideal body weight for
calculations with either G-CSF (G) or GGM-CSF, with a goal of
5106/kg CD34 cells. Patients were treated with growth factor sup-
port using GM-CSF beginning day 4 through ANC recovery of
1000. Blood product replacement was standardized to transfuse for
hemoglobin greater than 8gm/dl or platelet counts of10,000/mm3.
Viability was performed using ﬂow cytometry and propidium iodide.
Continuous variables were analyzed as means and 95% conﬁdence
intervals, but p-values were produced using a Wilcoxon Rank Sum
Test for non-normally distributed data. Categorical variables were
analyzed using a Fisher’s Exact Test.
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